CardioFocus to accelerate market expansion of HeartLight endoscopic ablation system

Ten cardiac centers across the U.S. have now initiated HeartLight endoscopic ablation system programs.

CardioFocus (Marlborough, MA) has completed its controlled U.S. commercial launch of the HeartLight endoscopic ablation system for treating paroxysmal atrial fibrillation (AF). Ten cardiac centers across the country have now initiated HeartLight programs.

Related: CardioFocus wraps $20M financing round to support endoscopic ablation system

The HeartLight system is a visually guided laser balloon technology for controlled and consistent pulmonary vein isolation (PVI) treatment of AF, offering direct visualization, titratable laser energy, and a universal balloon design. It provides an effective and safe treatment option for patients whose heart arrhythmias are insufficiently controlled with medication.

The company strategically partnered with select U.S. medical centers to execute the controlled launch of the HeartLight system, according to Paul LaViolette, CardioFocus' executive chairman. The company will also introduce its next-generation HeartLight Excalibur Balloon technology to the U.S. market in 2018, he says.

To rapidly advance U.S. product awareness, training, and customer adoption of the HeartLight system, the company has built a national sales force consisting of a team with more than 150 years combined experience in the fields of cardiology and electrophysiology. Through its direct efforts, the team has established a robust pipeline of more than 100 additional U.S. cardiology centers that have noted a strong interest in initiating HeartLight programs.

For more information, please visit

More in Biophotonics Tools